GlassScriptPhysician profile
Mohamed Ayad
NPI 1417924309
$14,201.28
in general payments reported to CMS, 2019-2025
65 companies · $1,713 in 2025
The $1,713 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,996 · 2020: $2,065 · 2021: $2,937 · 2022: $2,333 · 2023: $1,545 · 2024: $1,611 · 2025: $1,713.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,863 · Education: $6.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,862.74 |
| Education | $6.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,399.28 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $1,327.46 | 2019-2025 | Airsupra, Breztri |
| Ironwood Pharmaceuticals, INC | $1,046.23 | 2019-2025 | Linzess |
| Lilly USA, LLC | $1,042.64 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,017.89 | 2019-2025 | Jardiance |
| Pfizer INC. | $923.12 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $707.90 | 2019-2025 | Xifaxan |
| Novo Nordisk INC | $682.16 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $604.40 | 2021-2025 | Vraylar, Creon, Linzess |
| Amgen INC. | $532.74 | 2019-2025 | Repatha, Otezla, Otezla |
| Actelion Pharmaceuticals US, INC. | $371.69 | 2024-2025 | Uptravi, Opsumit |
| Allergan, INC. | $348.96 | 2019-2020 | |
| Ardelyx, INC. | $347.66 | 2022-2025 | Ibsrela |
| Novartis Pharmaceuticals Corporation | $278.77 | 2019-2023 | |
| Astellas Pharma US INC | $234.56 | 2019-2023 | Myrbetriq |
Show all 65 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohamed Ayad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.